Topics:

FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer

FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer

ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.

The drug has been on the market since 1991 and is also indicated for the treatment of osteolytic bone lesions of multiple myeloma, moderate-to-severe hypercalcemia of malignancy, and moderate-to-severe Paget's disease.

 
Loading comments...
Please Wait 20 seconds or click here to close